UBS cuts Neurocrine Biosciences stock price target to $214 on competition
UBS reduced its price target for Neurocrine Biosciences (NBIX) to $214 from $231, citing competition and safety concerns. The stock trades at 11x 2027 P/E, with a 14% EPS CAGR. Q2 sales for Ingrezza and Crenessity exceeded estimates. Other analysts maintain Buy ratings, but Vykat faces safety scrutiny.
How this was made
The 30-second read
Why it matters
Analyst target revisions create short‑term volatility; investors should watch for further safety data on Vykat.
Market read
Target revisions signal valuation reassessment for NBIX, potentially influencing biotech sector sentiment.
What to watch
Safety concerns around Vykat and competition for Crenessity could materialize into regulatory scrutiny, which may not be fully priced yet.
Background
UBS cut NBIX's price target amid competition and safety issues, while other houses raised theirs following strong Q2 results.
Ticker impact
UBS lowered its price target for Neurocrine Biosciences to $214, citing competition and safety concerns, while other analysts raised theirs.
likely modest downside as the lower UBS target may weigh on sentiment
UBS is a major sell‑side house; its target cut signals valuation concerns, but competing upgrades could offset the impact.
Market effects
Highlights competitive pressure in the neuro‑pharmacology space, potentially affecting peers with similar pipelines.
U.S. biotech sector may see slight re‑rating as analysts adjust expectations.
Limited to investors tracking biotech valuations; no broader market effect.
Counterpoint
Despite UBS's downgrade, the strong Q2 sales and multiple analyst upgrades suggest the stock may be undervalued.
Key entities
- companyNeurocrine Biosciences
Biotech firm developing Ingrezza, Crenessity, Vykat, and other neuro‑disorder therapies.
- analystUBS
Investment bank that lowered NBIX's price target to $214.
